TGTX

Latest SEC Filings & News for TGTX

2 most recent filings and news items mentioning TGTX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/TGTX/news?limit=20"

Pull TGTX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

RegulatoryJun 3, 2026Positive

TG Therapeutics reports positive Phase 1 data for subcutaneous BRIUMVI

TG Therapeutics announced positive pharmacokinetic and pharmacodynamic results from a Phase 1 trial of subcutaneous BRIUMVI, demonstrating greater than 60% bioavailability and supporting quarterly dosing. Phase 3 data is expected by end of 2026 or early 2027, with potential appro

View filing at SEC.gov →

RegulatoryMay 27, 2026Positive

TG Therapeutics Phase 3 ENHANCE trial meets primary endpoint for simplified BRIUMVI dosing

TG Therapeutics announced positive Phase 3 results showing bioequivalent drug exposure between a new single 600mg Day 1 infusion versus the current two-infusion regimen for BRIUMVI in multiple sclerosis patients. The company plans to file a supplemental BLA in 2H-2026, potentiall

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.